BriaCell Therapeutics Corp. (V:BCT*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 235 15th St
Tel: N/A
IR: See website
Key People
Jamieson Bondarenko
Chairman of the Board
William V. Williams
President, Chief Executive Officer, Director
Charles Louis Wiseman
Co-Founder, Director
Gadi Levin
Chief Financial Officer, Corporate Secretary
Business Overview
BriaCell Therapeutics Corp. is a Canada-based immuno-oncology biotechnology company, which develops treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab in patients with advanced breast cancer. The Company also is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients, and BriaDX, its companion diagnostic test. The Company's preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases.
Financial Overview
For the nine months ended 30 April 2019, Briacell Therapeutics Corp revenues was not reported. Net loss increased 25% to C$4.1M. Higher net loss reflects Research costs increase of 91% to C$3.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.03 to -C$0.02.
Reporting Currency: Canadian Dollars
Enterprise value: $11.99M as of Apr 30, 2019
Annual revenue (TTM): $0.00M as of Apr 30, 2019
EBITDA (TTM): -$6.40M as of Apr 30, 2019
Net annual income (TTM): -$6.24M as of Apr 30, 2019
Free cash flow (TTM): -$5.66M as of Apr 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 197,128,450 as of May 22, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization